Menaquinone-7 mioxazin 35aS)-18-((S)-2-((S)-1-((S)-2-acetamido-3-methylbutanoyl)pyrrolidine-2-carboxamido)-3-(3-chlorophenyl)propanamido)-27-(4-aminobutyl)-9-benzyl-30-butyl-24-(3-guanidinopropyl)-6-(hydroxymethyl)-21-isobutyl-3-methyl-1

35aS)-18-((S)-2-((S)-1-((S)-2-acetamido-3-methylbutanoyl)pyrrolidine-2-carboxamido)-3-(3-chlorophenyl)propanamido)-27-(4-aminobutyl)-9-benzyl-30-butyl-24-(3-guanidinopropyl)-6-(hydroxymethyl)-21-isobutyl-3-methyl-1

Smiles: O=C(C1=CC=CN=C1C1N=NN(CC2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=1C1C=CN=CC=1)C1=CC=CC=C1Cl

and IL-1β gene expressions in U937 macrophages by interfering with the activation of NF-κB

and AKT phosphorylation

Chemical Name: 4-{4-[3-(2-chlorophenyl)-1

Menaquinone-7 mioxazin 35aS)-18-((S)-2-((S)-1-((S)-2-acetamido-3-methylbutanoyl)pyrrolidine-2-carboxamido)-3-(3-chlorophenyl)propanamido)-27-(4-aminobutyl)-9-benzyl-30-butyl-24-(3-guanidinopropyl)-6-(hydroxymethyl)-21-isobutyl-3-methyl-1Menaquinone 7 (Vitamin K2 7), belongs to a class of K2 vitamin homologs, is originally discovered as the anti hemorrhagic factors. Menaquinone 7 (Vitamin K2 7) is identified as the most bioactive cofactor for the carboxylation reaction of Gla proteins . Supplementation with Menaquinone 7 (Vitamin K2 7) is a pharmacological option for activating matrix Gla protein and intervening in the progression of calcific aortic valve stenosis (CAVS). Product